GLPwatch

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

NCT05671653 · Terminated

Last updated 2026-05-28

This clinical trial is testing how an experimental GLP-1 drug called PF-07081532 affects the blood levels of birth control pills, omeprazole, and midazolam in healthy adults with obesity.

Status Terminated Stopped early and will not restart.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) basic-science study
Participants 32 people
Who can join Ages 18+ · female only Healthy volunteers accepted.
Timeline Started 2023-01 · est. completion 2023-11
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05671653 ↗

Description as written by the study sponsor.

Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide. The effect of these GLP-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. The effect of chronic PF-07081532 on single doses of the common stomach acid medication omeprazole, and common birth control medication blood levels will also be measured. The hypothesis is that chronic administration of the GLP-1 drugs will minimally affect blood levels from these common medications.

Treatments tested

Main thing measuredCohort 1: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Midazolam in Periods 1, 4 and 7
SponsorPfizer
Conditions studiedObesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05671653 ↗